Swedish pharmaceutical company Meda said Friday that it has inked an agreement to buy Acton Pharmaceuticals for $135 million. The transaction is expected to close during the fourth quarter of this year. Based in Marlborough, Mass., Acton Pharmaceuticals, which is backed by Sequoia Capital, is a specialty pharmaceutical company focused on treating respiratory conditions.
Nearly there!
A verification email is on its way to you. Please check your spam or junk folder just in case.
If you do not receive this within five minutes, please try to sign in again. If the problem persists, please email: subscriptions@pei.group .-
Sign in or Register
-
Issues with signing in? Click here
Don't have an account? Register now
-
